RCT | Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial – The Lancet Neurology (link to abstract – $ for full-text)

Commentary: Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy – Medscape (free registration required)